



PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/921,143-Conf. #6449
Filing Date	August 3, 2001
First Named Inventor	Timothy A. Coleman
Art Unit	1653
Examiner Name	Not Yet Assigned
Attorney Docket Number	PF112P6

RECEIVED

JUN 23 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
CQ	FX	US-6,040,157	03-21-2000	Hu et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁴ -Kind Code ⁴ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CQ	FY	International Search Report, Application No. PCT/US02/26246, mailed May 21, 2003	
	FZ	Statutory Declaration of Kari Alitalo, executed on August 14, 2002, and accompanying Exhibits KA-1 and KA-2	
	GA	Statutory Declaration of Peter Adrian Walton Rogers, executed on August 9, 2002	
	GB	Statutory Declaration of Francis John Ballard, executed on July 16, 2002	
	GC	Statutory Declaration of Kari Alitalo, executed on July 16, 2002, and accompanying Exhibit 1.	
	GD	Statutory Declaration of Susan Power, executed on March 22, 2002, and accompanying Appendices I to IV	
	GE	Statutory Declaration of Nicholas Kim Hayward, executed on March 26, 2002	
	GF	Statutory Declaration of Stuart A. Aaronson, executed on March 22, 2002, and accompanying Appendices I to III	
	GG	Statutory Declaration of Gary Baxter Cox, executed on March 22, 2002, and accompanying Exhibit GBC24 (Statutory Declaration of Peter Adrian Walters, executed on October 26, 2001)	
	GH	Statutory Declaration of Francis John Ballard, executed on December 12, 2001, and accompanying Exhibit 1	
	GI	Statutory Declaration of Kari Alitalo, executed on September 24, 2001, and accompanying Exhibits 1 and 2	
	GJ	Statutory Declaration of Peter Adrian Walton Rogers, executed on November 12, 2001, and accompanying Exhibits PAWR1 to PAWR14	
	GK	Statutory Declaration of John Stanley Mattick, executed on December 12, 2000, and accompanying Exhibits JSM1 to JSM4	

Examiner Signature	Date Considered	2/25/04
--------------------	-----------------	---------

Please type a plus sign (+) inside this box




PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/921,143
		Filing Date	August 3, 2001
		First Named Inventor	Coleman, T.
		Group Art Unit	1653
		Examiner Name	Unassigned
		Attorney Docket Number	PF112P6
Sheet	6	of	9



OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CA	DK	TSUJIMOTO <i>et al.</i> , "Analysis of the structure, transcripts, and protein products of <i>bcl-2</i> , the gene involved in human follicular lymphoma," <i>Proc. Natl. Acad. Sci (USA)</i> , 83:5214-5218 (1986).	
	DL	TISCHER <i>et al.</i> , "The Human Gene for Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> 266(18): 11947-11954 (1991).	
	DM	FRIEDMAN, T., "A brief history of gene therapy," <i>Nat. Genetics</i> 2:93-98 (1992).	
	DN	WILLIAMS, R.S. "Southwestern internal medicine conference: prospects for gene therapy of ischemic heart disease," <i>Am. J. Med. Sci.</i> 306(2): 129-136 (1993).	
	DO	HOCKEL <i>et al.</i> , "Therapeutic angiogenesis," <i>Arch. Surg.</i> 128:423-429 (1993).	
	DP	GUZMAN <i>et al.</i> "Efficient gene transfer into myocardium by direct injection of adenovirus vectors," <i>Circ. Res.</i> 73:1202-1207 (1993).	
	DQ	BELLOMO <i>et al.</i> , "Mice Lacking the Vascular Endothelial Growth Factor-B Gene (<i>Vegfb</i>) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac Ischemia," <i>Circ. Research</i> 89(2): e29-e35 (2000).	
	DR	COCKERILL <i>et al.</i> , "Angiogenesis: Models and Modulators" <i>Intl. Rev. Cytology</i> 159:113-160 (1995).	
	DS	GAMBLE <i>et al.</i> , "Regulation of In Vitro Capillary Tube Formation by Anti-Integrin Antibodies," <i>J. Cell. Bio.</i> 121(4): 931-943 (1993).	
	DT	GOLDSPIEL <i>et al.</i> , "Human Gene Therapy," <i>Clinical Pharmacy</i> 12: 488-505 (1993).	
	DU	GRIMMOND <i>et al.</i> , "Cloning and Characterization of a Novel Human Gene Related to Vascular Endothelial Growth Factor," <i>Genome Research</i> 6:124-131 (1996).	
	DV	HYDE <i>et al.</i> , "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," <i>Nature</i> 362: 250-255 (1993).	
	DW	KAY <i>et al.</i> , "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," <i>Science</i> 262:117-119 (1993).	
	DX	KOLODKA <i>et al.</i> , "Hepatic Gene Therapy: Efficient Retroviral-Mediated Gene Transfer into Rat Hepatocytes in Vivo," <i>Somatic Cell and Molecular Genetics</i> 19(5): 491-497 (1993).	
	DY	LITWIN <i>et al.</i> , "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> 101-129. <i>no year</i>	
	DZ	SHIBUYA <i>et al.</i> , "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> 519-524 (1990).	
	EA	SILINS <i>et al.</i> , "Analysis of the Promoter Region of the Human VEGF-Related Factor Gene," <i>Biochem. Biophys. Res. Comm.</i> 230: 413-418 (1997).	
✓	EB	STEWART <i>et al.</i> , "Insulin delivery by somatic cell gene therapy," <i>J of Mol. Endocrinology</i> 11: 335-341 (1993).	

Examiner Signature		Date Considered	2/25/04
--------------------	--	-----------------	---------

¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box




PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/921,143
		Filing Date	August 3, 2001
		First Named Inventor	Coleman, T.
		Group Art Unit	1653
		Examiner Name	Unassigned
Sheet	7	of	9
		Attorney Docket Number	PF112P6



OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CE	EC	TOWNSON <i>et al.</i> , "Characterization of the Murine VEGF-Related Factor Gene," <i>Biochem. & Biophys. Res. Comms.</i> 220: 922-928 (1996).	
	ED	WALSH <i>et al.</i> , "Gene Therapy for Human Hemoglobinopathies," <i>P.S.E.B.M.</i> 204: 289-300. <i>no year</i>	
	EF	YOUREY, <i>et al.</i> (2000) Vascular Endothelial Cell Growth Factors Promote the In Vitro Development of Rat Photoreceptor Cells. <i>J. Neuroscience</i> , 20: 6781 - 6788.	
	EG	YOUREY, <i>et al.</i> (1999) Vascular Endothelial Cell Growth Factor (VEGF)-2 Enhances the Development of Rat Photoreceptor Cells In Vitro. <i>Soc. Cell Biology</i> , 227. (Abstract provided)	
	EH	GenBank Accession No. X68203, APRELIKOVA <i>et al.</i> , "H.sapiens mRNA for FLT4, class III receptor tyrosine kinase," November 30, 1993.	
	EI	GenBank Accession No. M95200, CLAFFEY <i>et al.</i> , "Mouse vascular endothelial growth factor mRNA, complete cds," April 27, 1993.	
	EJ	GenBank Accession No. M24160, DIGNAM <i>et al.</i> , "C.tentans 185-kd secretory protein (sp185) mRNA, partial cds, clone pCt185," April 26, 1993.	
	EK	GenBank Accession No. M24276, DIGNAM <i>et al.</i> , "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.1," April 26, 1993.	
	EL	GenBank Accession No. M24277, DIGNAM <i>et al.</i> , "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.2," April 26, 1993.	
	EM	GenBank Accession No. D88689, FINNERTY <i>et al.</i> , "Mus musculus mRNA for flt-1, complete cds," April 14, 2000.	
	EN	GenBank Accession No. L07296, FINNERTY <i>et al.</i> , "Mus musculus receptor tyrosine kinase (FLT4) mRNA, complete cds," August 9, 1993.	
	EO	GenBank Accession No. X54936, MAGLIONE <i>et al.</i> , "H.sapiens mRNA for placenta growth factor (PIGF)," November 12, 1991.	
	EP	GenBank Accession No. S57152, MAGLIONE <i>et al.</i> , "Homo sapiens placenta growth factor 2 (PIGF-2) gene, partial cds," March 5, 2001.	
	EQ	GenBank Accession No. X59397, MATTHEWS <i>et al.</i> , "Mouse Flk-1 mRNA for a tyrosine kinase receptor," November 6, 1991.	
	ER	GenBank Accession No. X52263, PAULSSON <i>et al.</i> , "C.tentans balbiani ring 3 (BR3) gene," December 18, 1992.	
	ES	GenBank Accession No. M63971, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 1," August, 1993.	
	ET	GenBank Accession No. M63972, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 2," August 3, 1993.	

Examiner Signature		Date Considered	2/25/04
--------------------	--	-----------------	---------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box




PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/921,143		
		Filing Date	August 3, 2001		
		First Named Inventor	Coleman, T.		
		Group Art Unit	1653		
		Examiner Name	Unassigned		
Sheet	9	of	9	Attorney Docket Number	PF112P6



OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CA	FM	GenBank Accession No. K03215, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 9," January 13, 1995.	
	FN	GenBank Accession No. K03216, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 10, January 13, 1995.	
	FO	GenBank Accession No. K03217, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 11," January 13, 1995.	
	FP	GenBank Accession No. K03218, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 12," January 13, 1995.	
	FQ	GenBank Accession No. M13994, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-alpha protein, complete cds," October 31, 1994.	
	FR	GenBank Accession No. M13995, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-3-beta protein, complete cds," October 31, 1994.	
	FS	GenBank Accession No. L22473, OLTVAI <i>et al.</i> , "Human Bax alpha mRNA, complete cds," December 15, 1993.	
	FT	GenBank Accession No. L22474, OLTVAI <i>et al.</i> , "Human Bax beta mRNA, complete cds," December 13, 1993.	
	FU	GenBank Accession No. AJ000185, ACHEN <i>et al.</i> , "Homo Sapiens mRNA for vascular endothelial growth factor-D," February 11, 1998.	
	FV	International Search Report, Application No. PCT/US99/05021.	
	FW	International Search Report, Application No. PCT/US94/05291.	

Examiner Signature		Date Considered	2/25/04
--------------------	--	-----------------	---------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (07-05)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**ELEVENTH SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/921,143
Filing Date	August 3, 2001
First Named Inventor	Coleman, Timothy A.
Art Unit	1636
Examiner Name	Qian, Celine X.
Attorney Docket Number	1488.100000N/PAJ/LMB

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
/C.Q./	NPL50	Lee <i>et al.</i> , "Improved Expression of Vascular Endothelial Growth Factor by Naked DNA in Mouse Skeletal Muscles: Implication for Gene Therapy of Ischemic Diseases," <i>Biochem. Biophys. Res. Comm.</i> 272:230-235, Academic Press (May 2000)	
/C.Q./	NPL51	Walter <i>et al.</i> , "Local Gene Transfer of phVEGF-2 Plasmid by Gene-Eluting Stents," <i>Circulation</i> 110:36-45, American Heart Association, Inc. (June 2004)	

667640

Examiner Signature	Celine Qian	<small>Digitally signed by Celine Qian DN: cn=Celine Qian, c=US, o=USPTO, ou=1636, email=celine.qian@uspto.gov Date: 2007.05.14 11:07:31 -0400</small>	Date Considered	
-----------------------	-------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Please type a plus sign (+) inside this box

+

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number.	09/921,143
		Filing Date	August 3, 2001
		First Named Inventor	Coleman, T.
		Group Art Unit	1653
		Examiner Name	Unassigned
Sheet	1	of	9
		Attorney Docket Number	PF112P6



U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ³ (if known)			
✓	AA	6,040,157		Hu et al.	03-21-2000	
	AB	5,935,820		Hu et al.	08-10-1999	
	AC	5,932,540		Hu et al.	08-03-1999	
	AD	5,633,147		Meissner et al.	05-27-1999	
	AE	5,283,354		Lemischka	02-01-1994	
	AF	5,240,848		Keck et al.	08-31-1993	
	AG	5,234,908		Szabo et al.	08-10-1993	
	AH	5,194,596		Tischer et al.	03-16-1993	
	AI	5,861,301		Terman et al.	01-19-1999	
	AJ	5,840,693		Eriksson et al.	11-24-1999	
	AK	5,073,492		Chen et al.	12-17-1991	
	AL	5,219,739		Tischer et al.	06-15-1993	
	AM	5,326,695		Andersson et al.	07-05-1994	
	AN	5,607,918		Eriksson et al.	03-04-1997	
	AO	5,776,755		Alitalo et al.	07-07-1998	
	AP	08/510133		—	08/1995	
	AQ	08/585895		—	01/1996	
	AR	08/601132		—	02/1996	
	AS	08/671573		—	06/1996	
✓	AT	60/003491		—	09/1995	
	AU	08/554374		—	11/1995	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴			
Q	AV	WO	99/46364	Human Genome Sciences, Inc.	09-16-1999	
Q	AW	WO	98/33917	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.	06-08-1998	

Examiner Signature		Date Considered	2/25/04
--------------------	--	-----------------	---------

* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.